Evidence map›Paper›PMID 30514501›Full record

ArticleTuberculosis (Edinburgh, Scotland)2018

Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Tuhina Gupta, Monica LaGatta, Shelly Helms, Rebecca L Pavlicek, Simon O Owino, Kaori Sakamoto, Tamas Nagy, Stephen B Harvey, Mark Papania, Stephanie Ledden and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Dual oxidase 1 is dispensable duringFrontiers in immunology · 2023
    Article
  2. Article
  3. Article
  4. Review
  5. Ferrets as a model for tuberculosis transmission.Frontiers in cellular and infection microbiology · 2022
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Tuhina GuptaDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Monica LaGattaDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA; Pathens, Inc., Athens, GA, USA.
Shelly HelmsDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Rebecca L PavlicekDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Simon O OwinoDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA; Pathens, Inc., Athens, GA, USA.
Kaori SakamotoDepartment of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Tamas NagyDepartment of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Stephen B HarveyAnimal Resources Program, University of Georgia, Athens, GA, USA; Department of Population Heath, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Mark PapaniaCenters for Disease Control and Prevention, Atlanta, GA, USA.
Stephanie LeddenDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA.
Kevin T SchultzPathens, Inc., Athens, GA, USA.
Candace McCombsPathens, Inc., Athens, GA, USA.
Frederick D QuinnDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA; Pathens, Inc., Athens, GA, USA.
Russell K KarlsDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA; Pathens, Inc., Athens, GA, USA. Electronic address: rkarls@uga.edu.
University of Georgia · USProgram for Appropriate Technology in Health · USCenters for Disease Control and Prevention · US

Funding

A novel live intranasal TB vaccineR41AI100457 · NIAID · PATHENS, INC. · PI QUINN, FREDERICK D · 2012 to 2013
$600k
NIAID NIH HHS R41 AI100457
6 · The paper itself

Abstract

Tuberculosis (TB) is currently the leading cause of death in humans by a single infectious agent, Mycobacterium tuberculosis. The Bacillus Calmette-Guérin (BCG) vaccine prevents pulmonary TB with variable efficacy, but can cause life-threatening systemic infection in HIV-infected infants. In this study, TBvac85, a derivative of Mycobacterium shottsii expressing M. tuberculosis Antigen 85B, was examined as a safer alternative to BCG. Intranasal vaccination of guinea pigs with TBvac85, a naturally temperature-restricted species, resulted in serum Ag85B-specific IgG antibodies. Delivery of the vaccine by this route also induced protection equivalent to intradermal BCG based on organ bacterial burdens and lung pathology six weeks after aerosol challenge with M. tuberculosis strain Erdman. These results support the potential of TBvac85 as the basis of an effective TB vaccine. Next-generation derivatives expressing multiple M. tuberculosis immunogens are in development.

Indexed as

AcyltransferasesAdministration, IntranasalAerosolsAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsDisease Models, AnimalFemaleGuinea PigsImmunity, MucosalImmunogenicity, VaccineImmunoglobulin GLungMycobacterium tuberculosisNasal MucosaAcyltransferasesAerosolsAntibodies, Bacterialantigen 85B, Mycobacterium tuberculosisAntigens, BacterialBacterial ProteinsImmunoglobulin GTuberculosis VaccinesVaccines, DNAIntranasalMycobacteriumTBvac85TuberculosisVaccine

Identifiers

PMID30514501
PMCPMC6296365
OpenAlexW2897041325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.